メチルフェニダートは,子供と青少年における注意欠陥/多動性障害の治療法である
Ole J Storebø1, Erik Simonsen2, Christian Gluud3
1Psychiatric Research Unit, Child and Adolescent Psychiatric Department, Region Zealand Psychiatry, Region Zealand, Denmark.
JAMA
|May 11, 2016
まとめ
メチルフェニダートは注意欠陥/多動性障害 (ADHD) の症状と行動を改善する可能性があるが,証拠の質は低い. 薬はより軽度の副作用と関連しており,重度の副作用に関するデータは限られている.
科学分野:
- 小児神経学
- 児童・青少年精神科
- 薬理学について
背景:
- 注意欠陥/多動性障害 (ADHD) は,子供や青少年における一般的な神経発達障害である.
- メチルフェニダートはADHDの治療に広く処方されている刺激薬です.
- メチルフェニダートの利点と害を理解することは,臨床的意思決定に不可欠です.
研究 の 目的:
- メチルフェニダート治療と小児のADHDにおける結果の関連性を評価する.
- ADHDの子供と青少年におけるメチルフェニダートの潜在的利益と害の両方を評価する.
主な方法:
- ランダム化制御試験の体系的レビューとメタ解析
- 小児のADHD集団におけるメチルフェニダートの有効性と安全性を評価した研究を含む.
- ADHDの症状,一般的な行動,生活の質,有害事象の評価
主要な成果:
- メチルフェニダートはADHDの症状,一般的な行動,生活の質の改善と関連しています.
- これらの改善を裏付ける証拠の質は非常に低いため,その規模は不確実です.
- メチルフェニダートを使用すると,非重篤な有害事象のリスクが増加することが観察されました.
- 重篤な有害事象との関連を評価するには,十分なデータはありません.
結論:
- メチルフェニダートは,小児患者のADHDの症状,行動,および生活の質に対する潜在的な利点を示しています.
- これらの利点の臨床的意義は,非常に低品質な証拠のために不確実です.
- メチルフェニダートは,非重篤な有害事象の発生率の増加と関連しています.
- 特に重篤な有害事象に関して,安全性プロファイルを完全に確認するためにさらなる研究が必要である.
さらに関連する動画
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
6.6K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
11.1K
関連する概念動画
01:30Attention-Deficit/Hyperactivity Disorder
1.3K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.3K
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
1.1K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.1K
01:28Adrenergic Agonists: Mixed-Action Agents
1.7K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.7K
01:30Adrenergic Agonists: Therapeutic Uses
2.1K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.1K
01:25Adrenergic Agonists: Indirect-Acting Agents
3.0K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.0K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
809
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
809